Study Comparing Tafasitamab, Lenalidomide, and R-CHOP with R-CHOP Alone in Newly Diagnosed High-Risk DLBCL Patients

Inclusion Criteria

• Newly diagnosed with certain types of diffuse large B-cell lymphoma (DLBCL), confirmed by a biopsy.
• Must not have received any previous treatment for DLBCL.
• Must have a specific risk level based on age and other factors.
• Must start treatment within 28 days of diagnosis.
• Must be in good general health, with a performance status score of 0, 1, or 2.
• Must have a heart function of 50% or higher.
• Must have adequate blood cell counts and organ function.
• Women must agree to use birth control and undergo regular pregnancy tests.
• Men must agree to use condoms or remain abstinent during the study.

Exclusion Criteria

• Have a different type of lymphoma not included in the study.
• Have had another type of cancer, unless it was treated successfully and has been inactive for over two years.
• Have received any previous treatment for lymphoma, except for certain allowed pre-treatments.
• Have any known involvement of the central nervous system (CNS) by lymphoma.
• Have any active infections or a history of significant heart, brain, or other diseases that could interfere with the study.